AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04000191 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perianal ice application
Description: Application of ice to the perianal area after the area is prepared with betadine, prior to injection of local anesthesia by the surgeon.
Study NCT02476305 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cryoprobes
Description: Patient undergo percutaneous cryoablation of desmoid tumor, with cryoprobes
Study NCT05072821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A Injection [Botox]
Description: After the whole surgical procedures of keloid revision are done, the participants will receive Botulinum Toxin type A (BTA) injection. The investigators split the scar into the right side and the left side. BTA and 0.9% saline, respectively, are used for the two arms of the study. Vials containing 100 units of BTA (BotoxⓇ, Allergan) are mixed with 2mL 0.9% injectable saline. The injection depth will be the intradermal layer. Injections will be performed with a 30-gauge needle and 1 mL syringe. Just before skin closure, the entire scar was treated, with sides randomized to receive treatment with either BTA or 0.9% normal saline. The dosage is 8 units / cm based on aforementioned studies. The maximal dose won't exceed 100 units.
Study NCT05072821 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride Injection
Description: After the whole surgical procedures of keloid revision are done, the participants will receive 0.9% saline injection. The investigators split the scar into the right side and the left side. BTA and 0.9% saline, respectively, are used for the two arms of the study. Only 0.9% saline is injected on the control side. The injection depth will be the intradermal layer. Injections will be performed with a 30-gauge needle and 1 mL syringe. Just before skin closure, the entire scar was injected, with sides randomized to receive treatment with either BTA or 0.9% normal saline. The dosage is 0.16 mL / cm.
Study NCT02910687 — intervention group
Intervention type: OTHER
Intervention: This is an observational study
Study NCT03114358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Carbapenem de-escalation
Description: The intervention group is de-escalation carbapenems early within 24 hours or no later than 72 hours of prescription by ID specialist (early de-escalation).
Study NCT04423445 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laser acupuncture combined with acupressure
Description: Participants received laser acupuncture on the six selected acupuncture points bilaterally twice a week for 4 weeks. A seed was taped onto each of the three points of the unilateral ear (initially, the left ear), where it remained for five days. Pressing on each of the seeds for one minute three times a day was required, but the stimulation intensity was adjusted depending on the participant's individual tolerance. The de qi sensation appears to be an established intervention efficacy indicator during auricular acupressure. After five days, the seed was removed, and a new seed was taped on the other ear.
Study NCT04601493 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choice Architecture Nudge
Description: During the choice architecture nudge intervention, Primary Care Providers (PCPs) will be sent alerts in the Electronic Health Record (EHR) system when they initiate an opioid order for a patient who has not had an opioid prescription within the past six months. The alert provides guidance language about opioid prescribing and prompts the PCP to open the SmartSet to order non-opioid treatment alternatives. PCPs can choose to ignore this, but opening the SmartSet is the default option. When the SmartSet is opened, PCPs can choose to click on a variety of treatment order options, including both non-opioid pharmacological options and non-pharmacological options (e.g., referral to physical therapy or pain clinic).
Study NCT01616199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PX-866
Description: Phase 1 dose escalation: PX-866 in combination administered orally every day in 28-day cycles until progression or unacceptable toxicity.~Phase 2 combination: PX-866 and vemurafenib administered every day in 28 day cycles until progression or unacceptable toxicity.~Phase 2 single-agent: vemurafenib administered orally at labeled dose every day in 28 day cycles until progression or unacceptable toxicity.
Study NCT01616199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vemurafenib
Description: vemurafenib is a B-Raf enzyme inhibitor
Study NCT04601493 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PMP Integration & Nudge
Description: During the Prescription Drug Monitoring Program (PMP) integration \& nudge intervention, Primary Care Providers (PCPs) will have integrated access to the PMP embedded within the EHR. All clinicians can already access the PMP to look up a patient's prior opioid prescriptions and prescription fills. However, this process involves signing in to the separate PMP website and can be complicated and time-consuming within typical clinical workflow. The integrated PMP tool makes it much easier and faster for a PCP to access the PMP information for a given patient.
Study NCT01616199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vemurafenib
Description: vemurafenib is a B-Raf enzyme inhibitor
Study NCT02461238 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nutrition education
Description: Nutrition education workshops taught by a dietician
Study NCT02461238 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition education
Description: Nutrition education workshops taught by a dietician
Study NCT04689698 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Thomayer test
Description: Testing of the ankle in sagittal line and Thomayer test before and after flossing of sole.
Study NCT06048887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRN04894 Oral Solution
Description: CRN04894 is an orally active nonpeptide melanocortin 2 receptor (MC2R) or adrenocorticotropic hormone (ACTH) antagonist.
Study NCT06048887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Solution
Description: Placebo
Study NCT02342938 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MEG or fMRI And INtracranial EEG
Study NCT02342938 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fMRI
Study NCT04133675 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BTL Emsella
Description: The Emsella Chair is a novel high-intensity focused electromagnetic (HIFEM) technology for the treatment of SUI, in addition to other pelvic floor related disorders. HIFEM technology induces deep pelvic floor muscle contractions designed to deliver the equivalent of 11,200 Kegel exercises over 28 minutes. The treatment paradigm consists of 3 different phases. The phases consist of an intense stimulation of the pelvic floor muscles (PFM), which consists of stimlulation and relaxation. The repetition of the phases and focused electromagnetic energy delivery leads to pelvic floor stimulation, adaptation, and remodelation.
Study NCT04133675 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham BTL Emsella
Description: Sham subjects will be positioned on the device in the same manner as the active treatment group. The sham treatment will be provide some sensation without active HIFEM technology. The programming for the sham treatment will have an amplitude limitation, with the setting below therapeutic level (\<10% power).
Study NCT04334096 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: quality of life pathway
Description: The first quality of life (QoL) measurement is conducted in the hospital after surgery via a digital questionnaire (EORTC QLQ-C30, QLQ-BR23) on a tablet computer. Further QoL measures are accomplished via paper-pencil in the practice of the patient's physician during aftercare (3, 6, 9, 12, 18, 24 months after surgery). Paper questionnaires are transferred by fax to a local server, automatically processed, digitized and stored in a database, and transferred back to the physician's practice (email or fax depending on preference) in form of a QoL profile. The immediate response enables patient and physician to discuss the QoL profile right away. Specific therapeutic options for the treatment of QoL have been defined: psychotherapy, social counseling, pain therapy, physiotherapy, nutrition counseling, fitness. To provide continuous medical education, quality circles for each therapeutic option have been founded. Physicians receive a list with addresses of all quality circle members.
Study NCT04608201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine 7 mg/ 24h Transdermal Patch - 24 Hour
Description: Treatment involves escalating doses to the target dose of 14 mg / day~1. / Dose escalation:~   * Level 1: 3.5 mg/day (1/2 patch) for 2 days (D1 and D2)~  * Level 2: 7 mg/day (1 patch) for 2 days (D3 and D4)~  * Level 3: 10.5 mg/day (1.5 patch) for 2 days (D5 and D6)~  * Level 4: target dose = 14 mg/day (from D7 to discharge from hospital + 1 week or maximum 5 weeks after the start of treatment)~2. / Decrease in dose (1 week after exit from hospital or maximum 5 weeks after the start of treatment): Decrease of 3.5 mg (1/2 patch) per week (over 3 weeks maximum)
Study NCT04608201 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of NICOTINE Transdermal patch
Description: Placebo of nicotine patch administered to the same administration schedule as in the experimental arm
Study NCT04536506 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bobath Therapy
Description: Bobath group received 45 min of sessions three times weekly for 12 weeks. An individual program was scheduled for each case following pre-assessment. It was targeted to enable normal posture, facilitation of corrective balance and protective responses and development of normal movement patterns
Study NCT04536506 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vojta technique
Description: Vojta group received the following three times weekly for 12 weeks: 1. Reflex crawling, 2. First stage of reflex turning, 3. Second stage of reflex turning. Stimuli (pressure and stretch) for 30-60 sec were given by using the main stimulus points and auxiliary stimulus points together.
Study NCT01589601 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual heart failure care
Description: Usual heart failure care focused on symptom relief; assessment and management of anxiety, depression, and spiritual concerns; as well as advance care planning that includes definition of care goals, resuscitation preferences, and participation in the Outlook intervention.
Study NCT01589601 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interdisciplinary palliative care
Description: Interdisciplinary palliative care focused on symptom relief; assessment and management of anxiety, depression, and spiritual concerns; as well as advance care planning that includes definition of care goals, resuscitation preferences, and participation in the Outlook intervention.
Study NCT04006119 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad-RTS-hIL-12
Description: * intratumoral injection of Ad-RTS-hIL-12~* 2.0 x 10\^11 viral particles (vp) per injection
Study NCT04006119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veledimex
Description: 20mg/day 15 oral daily doses of veledimex
Study NCT04006119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab-Rwlc
Description: Infusion every 3 weeks (350mg)
Study NCT00199485 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Angelica Sinensis
Description: Angelica Sinensis / placebo
Study NCT04633616 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored Patient-Provider Communication
Description: Every 1.5 months, patients randomized to the tailored patient-provider communication model will receive weblinks directing patients to disease-specific educational videos and associated questionnaires. Communication will be tailored as the mode of weblink delivery will be customized to patient preference. Patients can choose messages to be delivered via e-mail, SMS, WhatsApp, or Facebook. For example, if one patient determines SMS messaging as their preferred communication mode, then this patient will receive a weblink via SMS directing the patient to customized educational videos and questionnaires. Weblinks delivered via tailored patient-provider communication will be enabled by Wecudos.
Study NCT04633616 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-Tailored Patient-Provider Communication
Description: Every 1.5 months, patients randomized to the non-tailored patient-provider communication model will receive weblinks directing patients to disease-specific educational videos and associated questionnaires. Communication will be non-tailored such that patients will not be able to choose their preferred mode of communication and will receive hardcopy. Patients will receive hardcopy on how to access psoriasis education. Weblinks delivered via non-tailored patient-provider communication will be enabled by Wecudos.
Study NCT03578809 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI6012
Description: MEDI6012
Study NCT03578809 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02474654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivicaine
Description: 15mg
Study NCT02474654 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivicaine
Description: 15mg
Study NCT02474654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: 15mcg
Study NCT04510740 — intervention group
Intervention type: OTHER
Intervention: Physician's choice according to patient's needs.
Description: Routine care as per site standard.
Study NCT03719300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inodiftagene vixteplasmid
Description: BC-819 at 20 mg/50 mL, instilled intravesically into the bladder, with a retention time of at least 30 minutes (up to 2 hours).~Induction Phase (weekly treatments): 10 weekly treatments; Maintenance Phase: treatment every 3 weeks for up to 84 additional weeks
Study NCT01384045 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health promotion outreach
Description: Calling patients who are due for diabetes related services, sending them an interventional letter and assisting them in getting over due serves.
Study NCT02768246 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BVGA
Description: The BVGA enables the direct connection of a bag valve device to a guedel, eliminating the need for a face mask during ventilation
Study NCT02768246 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Face Mask
Description: Classic face mask
Study NCT02919696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally
Study NCT02261792 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 24 hours Trendelenburg position
Description: Trendelenburg position
Study NCT04113720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine hydrochloride
Description: levobupivacaine 0.25%
Study NCT04113720 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine Hydrochloride + Dexmedetomidine
Description: Levobupivacaine plus Dexmedetomidine
Study NCT03225599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cranial Osteopathic Manipulative Medicine
Description: The hands will be placed on the head using the vault hold (bilateral thumbs are off the head, index fingers on the temporal bones, middle fingers on the sphenoid bones, ring fingers on the mastoid and the 5th fingers on the occipital bone). Diagnosis and treatment of restrictions palpated on the scalp will be made using this hand position
Study NCT02815410 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: levetiracetam
Description: Patients in this group are with newly diagnosed glioblastoma patients who are supposed to be treated with concurrent chemoradiotherapy (CCRT) and adjuvant chemotherapy with temozolomide (TMZ). Patients ( intervention Group) will be given levetiracetam (LEV) from the beginning of treatment till after the adjuvant chemotherapy with TMZ is over.
Study NCT03318900 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given IV
Study NCT02261792 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 24 hours bed rest
Description: 24 hours bed rest after EBP
Study NCT02261792 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EBP
Description: Autologous Epidural Blood Patch
Study NCT02261792 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EBP
Description: Autologous Epidural Blood Patch
Study NCT00909688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI-489
Study NCT00909688 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01248819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 60 mg
Description: Nebulization grou received intraperitoneal instillation of saline 20 ml on the gall bladder after induction of pneumoperitoneum but before dissection of gall bladder plus intraperitoneal nebulization of ropivacaine 1% 3 ml (30 mg) the start of gall bladder dissection and again at the end of surgery just before deflation of pneumoperitoneum (total of 60 mg). The first ropivacaine nebulization was performed over 5-6 minutes using the Aeroneb Pro® device through the umbilical port while the other ports were being inserted, while second nebulization was performed before the withdrawal of the ports
Study NCT03318900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD8-Positive T-Lymphocyte
Description: Given IV
Study NCT01248819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 100 mg
Description: Instillation group received intraperitoneal instillation of ropivacaine 0.5%, 20 ml (100 mg) on the gall bladder after induction of pneumoperitoneum but before dissection of gall bladder plus and intraperitoneal nebulization of normal saline 3 ml before the start of gall bladder dissection and again at the end of surgery just before deflation of pneumoperitoneum. The first saline nebulization was performed over 5-6 minutes using the Aeroneb Pro® device through the umbilical port while the other ports were being inserted, while second nebulization was performed before the withdrawal of the ports
Study NCT03579719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balovaptan
Description: In Period 1, balovaptan was administered orally once daily (qd) on Days 1 to 10.~In Period 2, balovaptan was administered qd on Days 6 to 20.
Study NCT03579719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: In Period 2, 200 mg itraconzole was administered bid for 4 days and qd on Days 5-20, approximately 12 hours apart. On Days 6-20, 200 mg itraconazole was administered qd.
Study NCT02565394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Micro Break with Dynamic Exercise Activities
Description: Surgeons may elect to activate a web application (video) and perform targeted intraoperative exercises.
Study NCT00576745 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vicryl Suture
Description: A 4-0 vicryl suture will be used to close the subcuticular layer
Study NCT00576745 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3M TM S Surgical Skin Closure System
Description: These steri-strips will be applied to close the skin in this cohort of patients
Study NCT03318900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT03318900 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Undergo leukapheresis
Study NCT03318900 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Utomilumab
Description: Given IV
Study NCT02474654 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 15mcg
Study NCT02856698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Dose use according to the product technical sheet
Study NCT02856698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Dose use according to the product technical sheet
Study NCT00776724 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxotere , Epirubicin
Description: Taxotere 70 mg/m2 1hr iv infusion / Epirubicin 90 mg/m2 (TE) iv infusion on day 1.
Study NCT00776724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E-HDFL,EP,TE,N-HDFL,NP,T-HDFL,TP
Description: Tau+ topo II+ ERCC1+ : Epi 45mg/m2 iv / 5FU 2000mg/m2 + Lv 300mg/m2 24 hrs infusion, day 1 and 8.~Tau+ topo II+ ERCC1- : Epi 45mg/m2 iv/ Cis 35mg/m2 24 hrs iv infusion day 1 and 8.~Tau+ topo II- ERCC1+ : Vin 25mg/m2 iv / 5FU 2000mg/m2 + Lv 300mg/m2 24 hrs infusion, day 1 and 8.~Tau+ topo II- ERCC1- : Cis 35mg/m2 24 hrs infusion / Vin 25mg/m2 iv day 1 and 8.~Tau- topo II+ ERCC1+ : Docetaxel 70 mg/m2 / Epirubicin 90 mg/m2 on day 1.~Tau- topo II+ ERCC1- : Docetaxel 70 mg/m2 / Epirubicin 90 mg/m2 on day 1.~Tau- topo II- ERCC1+ : Tax 35mg/m2 1hr infusion / 5FU 2000mg/m2 + Lv 300mg/m2 24 hrs infusion, day 1 and 8.~Tau- topo II- ERCC1- : Tax 35mg/m2 1hr infusion / Cis 35mg/m2 24 hrs infusion day 1 and 8.